AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...
AbbVie's Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, jumped from the 10th to fifth spot. The three that fell off the list from ...
(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...
AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...
Hosted on MSN2mon
Drug Ads Misinform Patients and Raise Health Care Costs“Now there’s Skyrizi, so you can be all in with clear ... such as serious allergic reactions and an increased likelihood of infection. Other risks are described online: liver problems ...
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback